Drug Trial Radar · NCT02219711
Phase 1/1b Study of MGCD516 in Patients With Advanced Cancer
Last checked: Nov 19, 2026Latest source record: Mar 6, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
193
Actual
Start
Aug 2014
Primary completion
Apr 27, 2022
Study completion Apr 27, 2022
Sponsor
- Lead sponsor
- Mirati Therapeutics Inc.Bristol Myers Squibb (BMY)
- Sponsor type
- Industry
- First posted
- Aug 19, 2014
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
MGCD516 is a receptor tyrosine kinase (RTK) inhibitor shown in preclinical models to inhibit a closely related spectrum of RTKs including MET, AXL, MER, and members of the VEGFR, PDGFR, DDR2, TRK and Eph families. In this study, MGCD516 is orally administered to patients with advanced solid tumor malignancies to evaluate its safety, pharmacokinetic, metabolism, pharmacodynamic and clinical activity profiles. During the Phase 1 segment, the dose and regimen of MGCD516 will be assessed; during the Phase 1b segment, the clinical activity of MGCD516 will be evaluated in selected patient populations. Patients anticipated to be enrolled in Phase 1b will be selected based upon having a tumor type, including but not limited to, non small cell lung cancer and head and neck cancer positive for specific activating MET, NTRK2, NTRK3, or DDR2 mutations, MET or KIT/PDGFRA/KDR gene amplification, selected gene rearrangements involving the MET, RET, AXL, NTRK1, or NTRK3 gene loci, or having loss of function mutations in the CBL gene. In addition patients with clear cell renal cell carcinoma refractory to angiogenesis inhibitors or metastatic prostate cancer with bone metastasis will be enrolled.
Conditions
- Advanced Cancer
Interventions
MGCD516Drug
MGCD516 is a small molecule inhibitor of several closely related receptor tyrosine kinases. MGCD516 capsules will be taken with water.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Type of dose limiting adverse eventTime frame: Up to 3 weeks on treatment
- Area under the plasma concentration versus time curve (AUC) of MGCD516Time frame: Up to 72 hours
- Peak Plasma Concentration (Cmax) of MGCD516Time frame: Up to 72 hours
Locations
43 sites in 2 countries. Site status is shown where the registry gives one.
University of Alabama
Birmingham, Alabama
University of California, San Diego
San Diego, California
University of California, San Francisco
San Francisco, California
Sarcoma Oncology Research Center
Santa Monica, California
Innovative Clinical Research Institute
Whittier, California
Rocky Mountain Cancer Center
Denver, Colorado
Holy Cross Michael & Dianne Bienes Comprehensive Cancer Center
Fort Lauderdale, Florida
Florida Cancer Affiliates
Ocala, Florida
Florida Cancer Specialists
Sarasota, Florida
Northwestern University
Chicago, Illinois
Rush University Medical Center
Chicago, Illinois
Ochsner Clinic Foundation
New Orleans, Louisiana
Maryland Oncology Hematology,
Rockville, Maryland
Massachusetts General Hospital
Boston, Massachusetts
University of Michigan
Ann Arbor, Michigan
Henry Ford Health System
Detroit, Michigan
Washington University Center for Advanced Medicine
St Louis, Missouri
CHI Health St Francis, Saint Francis Cancer Treatment Center
Grand Island, Nebraska
Oncology Hematology West PC, Nebraska Cancer Specialists
Omaha, Nebraska
University of New Mexico Cancer Research and Treatment Center
Albuquerque, New Mexico
Roswell Park Cancer Institute
Buffalo, New York
Columbia University
New York, New York
Montefiore Medical Center
The Bronx, New York
Oncology Hematology Care, Inc.
Cincinnati, Ohio
Guthrie Clinical Research
Sayre, Pennsylvania
St. Francis Cancer Center
Greenville, South Carolina
Sarah Cannon Research Institute
Nashville, Tennessee
Texas Oncology-Austin Midtown
Austin, Texas
Mary Crowley Cancer Research Center
Dallas, Texas
University of Texas, MD Anderson Cancer Center
Houston, Texas
Texas Oncology-Tyler
Tyler, Texas
The Huntsman Cancer Institute
Salt Lake City, Utah
Virginia Cancer Specialists
Fairfax, Virginia
Oncology and Hematology Associates of Southwest Virginia, Inc., Blue Ridge Cancer Care
Roanoke, Virginia
Seattle Cancer Care Alliance
Seattle, Washington
Northwest Cancer Specialists, P.C.
Vancouver, Washington
University of Wisconsin
Madison, Wisconsin
Chungbuk National University Hospital
Cheongju-si, South Korea
Keimyung University Dongsan Hospital
Daegu, South Korea
National Cancer Center
Goyang-si, South Korea
Showing 40 of 43 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.